2017 2017/05/29 First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan Kusatsu/Shiga, Japan — May 29, 2017 — Takara Bio Inc. (Takara Bio), today announced that the first patient with melanoma has been enrolled into Oncolytic Virus HF10(TBI-1401) phase II clinical trial in Japan on May 26, 2017. In this clinical study,... Read more
4Q Results, ended Mar 31, 2017（PDF） This article is translated from press release in Japanese for your convenience. Forward-Looking StatementsStatements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are... Read more
Takara Bio Medium-Term Management Plan FY2020（PDF） This article is translated from press release in Japanese for your convenience. Forward-Looking StatementsStatements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are... Read more
Takara Bio USA Holdings, Inc. completes acquisition of WaferGen Bio-systems, Inc. Mountain View, CA—March 1, 2017—Takara Bio USA Holdings, Inc. (“TBUSH”) announced that it has completed the acquisition of WaferGen Bio-systems, Inc. (“WaferGen”), WaferGen has become a wholly-owned subsidiary of TBUSH as of February 28, 2017 (US local time). Under the merger agreement executed with... Read more
2017 2017/01/30 Announcement on submission of the Clinical Trial Plan Notification for phase II clinical trial of Oncolytic virus HF10 in Japan Kusatsu/Shiga, Japan — January 30, 2017 — Takara Bio Inc. (Takara Bio), today announced that the Clinical Trial Notification was submitted to PMDA (Pharmaceuticals and Medical Devices Agency; Japanese regulatory agency) to conduct... Read more
2017 2017/01/24 Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of NY-ESO-1・siTCR gene therapy in Japan Kusatsu/Shiga, Japan — January 24, 2017 — Takara Bio Inc. (Takara Bio), today announced that it has submitted the Clinical Trial Notification for regenerative medicines to PMDA (Pharmaceuticals and Medical Devices Agency), Japanese... Read more
Takara Bio USA Holdings, Inc. completes acquisition of Rubicon Genomics, Inc. Mountain View, CA—January 18, 2017—Takara Bio USA Holdings, Inc. (“TBUSH”) announced that it has completed the acquisition of Rubicon Genomics, Inc. (“Rubicon”), Rubicon has become a wholly-owned subsidiary of TBUSH as of January 17, 2017 (US local time). Under the merger agreement executed with Rubicon,... Read more
2017 2017/01/11 Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of CAR gene therapy in Japan Kusatsu/Shiga, Japan — January 11, 2017 —Takara Bio Inc. (Takara Bio), today announced that it has submitted the Clinical Trial Notification for regenerative medicines to PMDA (Pharmaceuticals and Medical Devices Agency), Japanese regulatory... Read more
Takara Bio Signs Exclusive License Agreement with Otsuka for the Investigational Cancer Treatment HF10, an Oncolytic Virus Kusatsu/Shiga, Japan — December 15, 2016 — Takara Bio Inc. (Takara) announced today that it has entered into an exclusive license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for co-development and commercialization in Japan of the oncolytic virus... Read more
Takara Bio USA Holdings, Inc. and Rubicon Genomics Announce Merger Agreement Mountain View, CA and Ann Arbor, MI —December 15, 2016—Takara Bio USA Holdings, Inc. (“TBUSH”) and Rubicon Genomics, Inc. (“Rubicon”), today announced the signing of a merger agreement pursuant to which TBUSH will acquire Rubicon, a privately-owned company headquartered in Ann Arbor, Michigan. Rubicon... Read more